Luteolin monohydrate
Based on 96 publication(s) in Google Scholar
Luteolin (monohydrate) is the monohydrate of Luteolin. Luteolin (Luteoline), a flavonoid, is also a potent Nrf2 inhibitor. Luteolin has anti-inflammatory and anticancer properties, induces apoptosis and cell cycle arrest in multiple human cancer cell lines, including non-small lung cancer cells, and inhibits cell metastasis and angiogenesis.
For research use only. We do not sell to patients.
- Purity : 99.13%
- CAS No.: 6113-16-2
- Formula: C15H12O7
- Molecular Weight:304.25
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Luteolin monohydrate
More- Theranostics. 2024 Sep 3;14(14):5551-5570. [Abstract]
- Adv Sci (Weinh). 2026 Apr;13(19):e16106. [Abstract]
- Adv Sci (Weinh). 2025 Nov 21:e08472. [Abstract]
- Cell Death Dis. 2025 Oct 7;16(1):714. [Abstract]
- Phytomedicine. 2026 Jan:150:157740. [Abstract]
- Phytomedicine. 2026 Jan:150:157586. [Abstract]
- Phytomedicine. 2025 Oct:146:157117. [Abstract]
- Phytomedicine. 2025 Jul 25:143:156911. [Abstract]
- Phytomedicine. 2025 May:140:156484. [Abstract]
- Phytomedicine. 2024 Jul 25:130:155611. [Abstract]
- J Hazard Mater. 2026 Mar 15:506:141417. [Abstract]
- Food Chem. 2025 Dec 30:497:146992. [Abstract]
- Food Chem. 2025 Oct 15:489:144992. [Abstract]
- Food Chem. 2023 Mar 30;405(Pt A):134807. [Abstract]
- Food Res Int. 2025 Dec;222(Pt 1):117620. [Abstract]
- Int J Nanomedicine. 2025 Dec 28:20:15883-15899. [Abstract]
- Antioxidants (Basel). 2026 May 29;15(6):688. [Abstract]
- Phytother Res. 2023 Nov;37(11):5315-5327. [Abstract]
- Phytother Res. 2021 Nov;35(11):6228-6240. [Abstract]
- Free Radic Biol Med. 2023 Nov 1:208:530-544. [Abstract]
- Am J Chin Med. 2026 Apr 30:1-20. [Abstract]
- Am J Chin Med. 2025 Aug 30:1-32. [Abstract]
- Chin Med. 2024 Mar 18;19(1):48. [Abstract]
- Cancer Cell Int. 2023 Sep 25;23(1):213. [Abstract]
- J Ethnopharmacol. 2026 May 23:363:121393. [Abstract]
- J Ethnopharmacol. 2025 Jan 13:339:119157. [Abstract]
- J Ethnopharmacol. 2024 Nov 15:334:118576. [Abstract]
- J Ethnopharmacol. 2023 Dec 5:317:116773. [Abstract]
- J Agric Food Chem. 2022 May 25;70(20):6134-6144. [Abstract]
- Life Sci. 2026 Jul 15:397:124440. [Abstract]
- Ind Crops Prod. 2026 Jan 22;241:122697.
- Ind Crops Prod. 2025 Dec 11;239:122458.
- Food Funct. 2024 Feb 19;15(4):2144-2153. [Abstract]
- Eur J Pharmacol. 2025 Dec 5:1008:178355. [Abstract]
- Eur J Pharmacol. 2025 Oct 5:1004:177984. [Abstract]
- Pharmaceuticals (Basel). 2023 Jul 7;16(7):975. [Abstract]
- Int J Mol Sci. 2026 May 12;27(10):4310. [Abstract]
- Int J Mol Sci. 2025 Jun 15;26(12):5739. [Abstract]
- Biomolecules. 2025 Jun 16;15(6):873. [Abstract]
- Front Pharmacol. 2023 Oct 31:14:1255069. [Abstract]
- Front Pharmacol. 2021 Apr 15:12:663551. [Abstract]
- Front Pharmacol. 2018 Jun 13:9:620. [Abstract]
- Chem Biol Interact. 2025 Sep 5:111738. [Abstract]
- Bioorg Chem. 2024 Jun:147:107412. [Abstract]
- Sci Rep. 2025 Nov 26;15(1):42044. [Abstract]
- Sci Rep. 2025 Jul 7;15(1):24311. [Abstract]
- Sci Rep. 2025 Apr 11;15(1):12398. [Abstract]
- Eur J Med Res. 2026 Mar 9. [Abstract]
- Pestic Biochem Physiol. 2025 Dec:215:106655. [Abstract]
- Cancers (Basel). 2023 Jul 24;15(14):3741. [Abstract]
- Cancers (Basel). 2023 Jan 16;15(2):548. [Abstract]
- J Inflamm Res. 2021 Dec 16;14:6939-6958. [Abstract]
- Poult Sci. 2026 Jan 12;105(3):106426. [Abstract]
- Mol Divers. 2025 Jan 16. [Abstract]
- Fish Shellfish Immunol. 2025 Nov:166:110633. [Abstract]
- Am J Physiol Endocrinol Metab. 2021 Jun 1;320(6):E1085-E1092. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2026 Jun 23. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Oct 29. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):6837-6850. [Abstract]
- J Chromatogr A. 2022 Aug 16:1677:463329. [Abstract]
- Biochim Biophys Acta Mol Cell Biol Lipids. 2025 Aug;1870(6):159635. [Abstract]
- Ren Fail. 2023 Dec;45(1):2184654. [Abstract]
- Clin Exp Metastasis. 2026 Jul 14;43(4):35. [Abstract]
- Int J Biochem Cell Biol. 2026 May:194:106909. [Abstract]
- BMC Pharmacol Toxicol. 2024 Jul 12;25(1):40. [Abstract]
- Comput Biol Chem. 2025 Oct 15;120(Pt 2):108721. [Abstract]
- Infect Drug Resist. 2025 Jul 3:18:3257-3277. [Abstract]
- Pharm Dev Technol. 2025 Nov;30(10):1543-1556. [Abstract]
- Biomed Res Int. 2022 Jul 23:2022:8080679. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Discov Oncol. 2025 Aug 8;16(1):1506. [Abstract]
- Vet Microbiol. 2022 Oct:273:109527. [Abstract]
- Shock. 2023 Aug 1;60(2):306-314. [Abstract]
- Toxicol In Vitro. 2020 Jun:65:104825. [Abstract]
- Cancer Rep (Hoboken). 2025 May;8(5):e70169. [Abstract]
- Oncol Lett. 2026 Apr 27;31(6):265.
- Medicine. 2023 Oct 13;102(41):e35384. [Abstract]
- Biol Pharm Bull. 2025;48(10):1514-1525. [Abstract]
- Biol Pharm Bull. 2022;45(8):1116-1123. [Abstract]
- Int Ophthalmol. 2025 Nov 19;45(1):494. [Abstract]
- Lett Drug Des Discov. 2026 Jan 10.
- Nat Prod Commun. 2025 Dec 17.
- Int J Clin Exp Pathol. 2022 May 15;15(5):206-214. [Abstract]
- Res Sq. 2026 Feb 24.
- SSRN. 2026 Jan 15.
- bioRxiv. 2025 Oct 3.
- SSRN. 2025 Jul 8.
- Res Sq. 2025 Jul 11.
- Biomed Pharmacother. 2024 Jul:176:116847. [Abstract]
- Phytomed Plus. 2023 Sep 1, 100483.
- Research Square Preprint. 2023 Sep 18.
- Oxid Med Cell Longev. 2023 Feb 10:2023:6726654. [Abstract]
- Contrast Media Mol Imaging. 2022 Aug 18:2022:3517020. [Abstract]
- Oxid Med Cell Longev. 2022 Apr 25;2022:3846217. [Abstract]
- Evid Based Complement Alternat Med. 2021 Nov 27:2021:7765658. [Abstract]
- Evid Based Complement Alternat Med. 2021 Aug 26:2021:7169211. [Abstract]
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
-
IF
-
Histological Imaging/Staining
-
WB
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 6113-16-2
-
Appearance Solid
-
Molecular Weight 304.25
-
Formula C15H12O7
-
Color Light yellow to yellow
-
SMILES
O=C1C=C(C2=CC(O)=C(O)C=C2)OC3=C1C(O)=CC(O)=C3.O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (96)
-
Journal Impact Factor
-
Most Recent
-
Theranostics
The m6A reader YTHDC2 promotes the pathophysiology of temporal lobe epilepsy by modulating SLC7A11-dependent glutamate dysregulation in astrocytes. [Abstract]2024 Sep 3;14(14):5551-5570. PMID: 39310099
Luteolin monohydrate purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Sep 3;14(14):5551-5570. [Abstract]
Luteolin (25 mg/kg, i.p., daily). Immunofluorescence analysis of astrocytes co-stained with NRF2 in the CA1 region of mice across different groups. Treatment with Luteolin, an NRF2 inhibitor, results in a reduction of NRF2 expression.
-
Adv Sci (Weinh)
GALNT10 Affects O-Glycosylation of IGFBP7 to Promote Tumor Vascular Remodeling and Metastasis of Ovarian Cancer. [Abstract]2026 Apr;13(19):e16106. PMID: 41637621 -
Adv Sci (Weinh)
Targeted Inhibition of CD74+ Macrophages by Luteolin via CEBPB/P65 Signaling Ameliorates Osteoarthritis Progression. [Abstract]2025 Nov 21:e08472. PMID: 41268703 -
Cell Death Dis
Mechanisms and targeted prevention of abnormal ductular reaction caused by a low concentration of Benzo(a)pyrene. [Abstract]2025 Oct 7;16(1):714. PMID: 41057340
Luteolin monohydrate purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Oct 7;16(1):714. [Abstract]
Luteolin (10 mg/kg; p.o.; daily for 4 weeks). Biochemical analysis of blood in NC, luteolin, B[a]P and B[a]P + luteolin groups.
-
Phytomedicine
Bruceantin inhibits the c-Myc/RL27A axis to suppress tumor progression in hepatocellular carcinoma. [Abstract]2026 Jan:150:157740. PMID: 41477978 -
Phytomedicine
Study on the anti-liver cirrhosis of Fuzheng Huayu tablet : Targeting macrophage PPARα axis-fatty acid metabolic. [Abstract]2026 Jan:150:157586. PMID: 41380414 -
Phytomedicine
Luteolin Induces GPX4-dependent Ferroptosis and Enhances Immune Activation in Colon Cancer. [Abstract]2025 Oct:146:157117. PMID: 40812220
Luteolin monohydrate purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Oct:146:157117. [Abstract]
Luteolin (0-100 μM; 48 h). Cell viability of MC38 and CT26 cells treated with varying concentrations of luteolin is assessed using the CCK-8 assay.
-
Phytomedicine
CBX5 loss drives Pl3Kδ inhibitor resistance in mantle cell lymphoma and propolis restores sensitivity by inducing CBX5-mediated ferroptosis. [Abstract]2025 Jul 25:143:156911. PMID: 40466505 -
Phytomedicine
Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]2025 May:140:156484. PMID: 40090046 -
Phytomedicine
Effect of luteolin on glioblastoma's immune microenvironment and tumor growth suppression. [Abstract]2024 Jul 25:130:155611. PMID: 38776737
Luteolin monohydrate purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Jul 25:130:155611. [Abstract]
Luteolin (60-120 μM; injected into the basal ganglia of the mice using a microsyringe; a total injection time of no less than 5 min). Hematoxylin and eosin staining of intracranial tumor plantation shows the tumor size in the coronal location of four groups.
-
J Hazard Mater
Ammonia-induced exosomal miRNA disrupts autophagy and promotes lung injury: Therapeutic potential of natural compounds. [Abstract]2026 Mar 15:506:141417. PMID: 41775203 -
Food Chem
Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]2025 Dec 30:497:146992. PMID: 41285060 -
Food Chem
Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]2025 Oct 15:489:144992. PMID: 40466530 -
Food Chem
Discovery of novel ascorbic acid derivatives and other metabolites in fruit of Rosa roxburghii Tratt through untargeted metabolomics and feature-based molecular networking. [Abstract]2023 Mar 30;405(Pt A):134807. PMID: 36370576 -
Food Res Int
Glycyrrhiza uralensis Fisch: A novel source of analgesic activity through NaV1.8 sodium channel modulation. [Abstract]2025 Dec;222(Pt 1):117620. PMID: 41267240 -
Int J Nanomedicine
Targeted Sustained-Release Therapy for Vulnerable Atherosclerotic Plaques Using Luteolin-Loaded Nanoparticles. [Abstract]2025 Dec 28:20:15883-15899. PMID: 41488864 -
Antioxidants (Basel)
Bioactive Extracts and Constituents from Taraxacum mongolicum: Antioxidant, Anti-Inflammatory, Enzyme-Inhibitory, and Molecular Docking Studies. [Abstract]2026 May 29;15(6):688. PMID: 42351994 -
Phytother Res
2023 Nov;37(11):5315-5327. PMID: 37469042 -
Phytother Res
Luteolin combined with low-dose paclitaxel synergistically inhibits epithelial-mesenchymal transition and induces cell apoptosis on esophageal carcinoma in vitro and in vivo. [Abstract]2021 Nov;35(11):6228-6240. PMID: 34494324 -
Free Radic Biol Med
Luteolin exhibits synergistic therapeutic efficacy with erastin to induce ferroptosis in colon cancer cells through the HIC1-mediated inhibition of GPX4 expression. [Abstract]2023 Nov 1:208:530-544. PMID: 37717793 -
Am J Chin Med
Mechanism of Quercetin and Luteolin on Colon Cancer Metastasis: Network Pharmacological Study and Experimental Validation. [Abstract]2026 Apr 30:1-20. PMID: 42057261 -
Am J Chin Med
Identification of Flavonoid Compounds in Treating Alzheimer's Disease Based on Network Medicine Framework Strategy. [Abstract]2025 Aug 30:1-32. PMID: 40884807 -
Chin Med
The combination of Schisandrin C and Luteolin synergistically attenuates hepatitis B virus infection via repressing HBV replication and promoting cGAS-STING pathway activation in macrophages. [Abstract]2024 Mar 18;19(1):48. PMID: 38500179 -
Cancer Cell Int
Network pharmacology and experimental verification-based strategy for exploring the mechanisms of luteolin in the treatment of osteosarcoma. [Abstract]2023 Sep 25;23(1):213. PMID: 37749554 -
J Ethnopharmacol
Dandelion (Taraxacum mongolicum Hand. -Mazz.) extract inhibits triple-negative breast cancer by inducing ferroptosis via NCOA4-mediated ferritinophagy. [Abstract]2026 May 23:363:121393. PMID: 41707813 -
J Ethnopharmacol
Luteolin modulates macrophage phenotypic switching via the AMPK-PPARγ pathway to alleviate ulcerative colitis in mice. [Abstract]2025 Jan 13:339:119157. PMID: 39603400 -
J Ethnopharmacol
Integrating UHPLC-Q-TOF-MS/MS, network pharmacology, bioinformatics and experimental validation to uncover the anti-cancer mechanisms of TiaoPi AnChang decoction in colorectal cancer. [Abstract]2024 Nov 15:334:118576. PMID: 39002822 -
J Ethnopharmacol
Research into the anti-pulmonary fibrosis mechanism of Renshen Pingfei formula based on network pharmacology, metabolomics, and verification of AMPK/PPAR-γ pathway of active ingredients. [Abstract]2023 Dec 5:317:116773. PMID: 37308028 -
J Agric Food Chem
2022 May 25;70(20):6134-6144. PMID: 35544338 -
Life Sci
Targeting the AMPK/ACC pathway with luteolin suppresses de novo lipogenesis and limits tumor burden in a MASH-HCC mouse model. [Abstract]2026 Jul 15:397:124440. PMID: 42097399 -
-
-
Food Funct
A Capsicum annuum L. seed extract exerts anti-neuroexcitotoxicity in HT22 hippocampal neurons. [Abstract]2024 Feb 19;15(4):2144-2153. PMID: 38305768 -
Eur J Pharmacol
NF-κB/TOM6/PINK1-mediated mitophagy attenuates vascular calcification: Luteolin as a therapeutic modulator. [Abstract]2025 Dec 5:1008:178355. PMID: 41232657 -
Eur J Pharmacol
Luteolin targets peroxiredoxin 2 to augment T-cell-mediated cytotoxicity and suppress lung adenocarcinoma progression. [Abstract]2025 Oct 5:1004:177984. PMID: 40712879 -
Pharmaceuticals (Basel)
Luteolin Protects Pancreatic β Cells against Apoptosis through Regulation of Autophagy and ROS Clearance. [Abstract]2023 Jul 7;16(7):975. PMID: 37513887 -
Int J Mol Sci
The Role and Mechanism of Nrf2 in Ameliorating Oxidative Stress and Inflammation in IR Mice by Aerobic Exercise. [Abstract]2026 May 12;27(10):4310. PMID: 42196296 -
Int J Mol Sci
Luteolin Potentially Alleviates Methamphetamine Withdrawal-Induced Negative Emotions and Cognitive Deficits Through the AKT/FOXO1/HO-1 Signaling Pathway in the Prefrontal Cortex and Caudate Putamen. [Abstract]2025 Jun 15;26(12):5739. PMID: 40565203 -
Biomolecules
Targeting Cellular Senescence to Enhance Human Endometrial Stromal Cell Decidualization and Inhibit Their Migration. [Abstract]2025 Jun 16;15(6):873. PMID: 40563513 -
Front Pharmacol
2023 Oct 31:14:1255069. PMID: 38026984 -
Front Pharmacol
Luteolin Ameliorates Experimental Pulmonary Arterial Hypertension via Suppressing Hippo-YAP/PI3K/AKT Signaling Pathway. [Abstract]2021 Apr 15:12:663551. PMID: 33935785 -
Front Pharmacol
Exploring the Therapeutic Mechanism of Desmodium styracifolium on Oxalate Crystal-Induced Kidney Injuries Using Comprehensive Approaches Based on Proteomics and Network Pharmacology. [Abstract]2018 Jun 13:9:620. PMID: 29950996
Luteolin monohydrate purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Jun 13:9:620. [Abstract]
Effects of Luteolin on the level of CTSD and p-CDK2 in HK-2 cells. The western blotting results of CTSD and p-CDK2 in the NaOx-stimulated HK-2 cells treated by Luteolin.
-
Chem Biol Interact
Involvement of ductal reaction in Di-(2-ethylhexyl)-phthalate-caused hepatic fibrosis: Molecular mechanisms and potential intervention strategies. [Abstract]2025 Sep 5:111738. PMID: 40915524 -
Bioorg Chem
Identification of FTY720 and COH29 as novel topoisomerase I catalytic inhibitors by experimental and computational studies. [Abstract]2024 Jun:147:107412. PMID: 38696845 -
Sci Rep
The mechanism of luteolin suppressing pancreatic cancer (PC) via cyclin B1 (CCNB1)-mediated signalling. [Abstract]2025 Nov 26;15(1):42044. PMID: 41298459 -
Sci Rep
2025 Jul 7;15(1):24311. PMID: 40624153 -
Sci Rep
Study on the regulatory mechanism of luteolin inhibiting WDR72 on the proliferation and metastasis of non small cell lung cancer. [Abstract]2025 Apr 11;15(1):12398. PMID: 40216870 -
Eur J Med Res
Integrative analysis reveals luteolin's molecular targets and mechanisms in pancreatic cancer treatment. [Abstract]2026 Mar 9. PMID: 41803987 -
Pestic Biochem Physiol
Mechanistic insights into chlorogenic acid and caffeic acid as novel juvenile hormone antagonists. [Abstract]2025 Dec:215:106655. PMID: 41162045 -
Cancers (Basel)
Optimization of a Luteolin-Loaded TPGS/Poloxamer 407 Nanomicelle: The Effects of Copolymers, Hydration Temperature and Duration, and Freezing Temperature on Encapsulation Efficiency, Particle Size, and Solubility. [Abstract]2023 Jul 24;15(14):3741. PMID: 37509402 -
Cancers (Basel)
Synergistic Combination of Luteolin and Asiatic Acid on Cervical Cancer In Vitro and In Vivo. [Abstract]2023 Jan 16;15(2):548. PMID: 36672499 -
J Inflamm Res
Computational Systems Pharmacology, Molecular Docking and Experiments Reveal the Protective Mechanism of Li-Da-Qian Mixture in the Treatment of Glomerulonephritis. [Abstract]2021 Dec 16;14:6939-6958. PMID: 34949932 -
Poult Sci
Targeting TatD nuclease and the MAPK Pathway: Luteolin multifaceted approach against Mycoplasma gallisepticum infection. [Abstract]2026 Jan 12;105(3):106426. PMID: 41548475 -
Mol Divers
Investigating the molecular mechanism of epimedium herb in treating rheumatoid arthritis through network pharmacology, molecular docking, and experimental validation. [Abstract]2025 Jan 16. PMID: 39821498 -
Fish Shellfish Immunol
Emodin enhances host antiviral immunity against Micropterus salmoides rhabdovirus by activating RLR signaling in largemouth bass. [Abstract]2025 Nov:166:110633. PMID: 40769268 -
Am J Physiol Endocrinol Metab
Luteolin alleviates polycystic ovary syndrome in rats by resolving insulin resistance and oxidative stress. [Abstract]2021 Jun 1;320(6):E1085-E1092. PMID: 33900851 -
Naunyn Schmiedebergs Arch Pharmacol
From network prediction to in vivo validation: luteolin attenuates cholestatic liver injury in association with PI3K/Akt/GSK-3β signalling modulation. [Abstract]2026 Jun 23. PMID: 42331983 -
Naunyn Schmiedebergs Arch Pharmacol
Phytochemical characterization and multi-target mechanism of Gleditsia sinensis Fructus in lung adenocarcinoma treatment. [Abstract]2025 Oct 29. PMID: 41160117 -
Naunyn Schmiedebergs Arch Pharmacol
Mechanism of Sophorae Flavescentis Radix against ovarian cancer via new pharmacology, molecular docking, and experimental verification. [Abstract]2024 Sep;397(9):6837-6850. PMID: 38561549 -
J Chromatogr A
Quality by Design in optimizing the extraction of (poly)phenolic compounds from Vaccinium myrtillus berries. [Abstract]2022 Aug 16:1677:463329. PMID: 35863094 -
Biochim Biophys Acta Mol Cell Biol Lipids
Lauric acid ameliorates excessive linoleic acid induced macrophage inflammatory response and oxidative stress in large yellow croaker (Larimichthys crocea). [Abstract]2025 Aug;1870(6):159635. PMID: 40383251 -
Ren Fail
Forecast and verification of the active compounds and latent targets of Guyuan decoction in treating frequently relapsing nephrotic syndrome based on network pharmacology. [Abstract]2023 Dec;45(1):2184654. PMID: 36866869 -
Clin Exp Metastasis
Luteolin inhibits hyperglycemia-induced epithelial-mesenchymal transition and malignant progression in gastric cancer via targeting AKR1B1-mediated glucose metabolism. [Abstract]2026 Jul 14;43(4):35. PMID: 42446820 -
Int J Biochem Cell Biol
Luteolin prevents hyperoxaluria-induced renal injury by inhibiting crystal deposition and renal inflammation. [Abstract]2026 May:194:106909. PMID: 41672398 -
BMC Pharmacol Toxicol
Effect of luteolin on oxidative stress and inflammation in the human osteoblast cell line hFOB1.19 in an inflammatory microenvironment. [Abstract]2024 Jul 12;25(1):40. PMID: 38997762 -
Comput Biol Chem
Integrated strategy of serum metabolomics, network pharmacology and experimental validation on revealing the bioactive metabolites and mechanism of Lycium ruthenicum Murr. against colorectal carcinoma. [Abstract]2025 Oct 15;120(Pt 2):108721. PMID: 41105991 -
Infect Drug Resist
Investigating the Therapeutic Mechanisms of Honeysuckle (China) in Sepsis Through Network Pharmacology and Experimental Validation. [Abstract]2025 Jul 3:18:3257-3277. PMID: 40630747 -
Pharm Dev Technol
Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia. [Abstract]2025 Nov;30(10):1543-1556. PMID: 41255224 -
Biomed Res Int
Network-Based Pharmacology and Bioinformatics Study on the Mechanism of Action of Gujiansan in the Treatment of Steroid-Induced Avascular Necrosis of the Femoral Head. [Abstract]2022 Jul 23:2022:8080679. PMID: 35915795 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Discov Oncol
Identification of potential molecular targets of luteolin in the treatment of hepatocellular carcinoma based on network pharmacology and transcriptome sequencing technology. [Abstract]2025 Aug 8;16(1):1506. PMID: 40778996 -
Vet Microbiol
Luteolin restricts ASFV replication by regulating the NF-κB/STAT3/ATF6 signaling pathway. [Abstract]2022 Oct:273:109527. PMID: 35961273 -
Shock
A network pharmacology-based treatment analysis of luteolin for regulating pyroptosis in acute lung injury. [Abstract]2023 Aug 1;60(2):306-314. PMID: 37379125 -
Toxicol In Vitro
Nonhomologous end joining and homologous recombination involved in luteolin-induced DNA damage in DT40 cells. [Abstract]2020 Jun:65:104825. PMID: 32169435 -
Cancer Rep (Hoboken)
Unraveling the Anti-Tumor Effects and Molecular Mechanisms of Hairyvein Agrimonia Herb in Gastric Cancer Through Network Pharmacology and Experimental Validation. [Abstract]2025 May;8(5):e70169. PMID: 40391580 -
-
Medicine
Network pharmacology-based strategy for predicting therapy targets of Ecliptae Herba on breast cancer. [Abstract]2023 Oct 13;102(41):e35384. PMID: 37832105 -
Biol Pharm Bull
He-Wei-Decoction Ameliorates Chronic Atrophic Gastritis via Modulation of the TLR4/NF-κB Signaling Pathway. [Abstract]2025;48(10):1514-1525. PMID: 41083380 -
Biol Pharm Bull
Regioselective Glucuronidation of Flavones at C5, C7, and C4' Positions in Human Liver and Intestinal Microsomes: Comparison among Apigenin, Acacetin, and Genkwanin. [Abstract]2022;45(8):1116-1123. PMID: 35908893 -
Int Ophthalmol
2025 Nov 19;45(1):494. PMID: 41258543 -
-
-
Int J Clin Exp Pathol
Myocyte enhancer factor 2D promotes hepatocellular carcinoma through AMOTL2/YAP signaling that inhibited by luteolin. [Abstract]2022 May 15;15(5):206-214. PMID: 35698637 -
-
-
-
-
-
Biomed Pharmacother
Decrease in GPSM2 mediated by the natural product luteolin contributes to colon adenocarcinoma treatment and increases the sensitivity to fluorouracil. [Abstract]2024 Jul:176:116847. PMID: 38823277 -
-
-
Oxid Med Cell Longev
JFD, a Novel Natural Inhibitor of Keap1 Alkylation, Suppresses Intracellular Mycobacterium Tuberculosis Growth through Keap1/Nrf2/SOD2-Mediated ROS Accumulation. [Abstract]2023 Feb 10:2023:6726654. PMID: 36819778 -
Contrast Media Mol Imaging
Luteolin Inhibited the Self-Renewal and Altered the Polarization of Primary Alveolar Macrophages. [Abstract]2022 Aug 18:2022:3517020. PMID: 36051934 -
Oxid Med Cell Longev
HO-1 Contributes to Luteolin-Triggered Ferroptosis in Clear Cell Renal Cell Carcinoma via Increasing the Labile Iron Pool and Promoting Lipid Peroxidation. [Abstract]2022 Apr 25;2022:3846217. PMID: 35656025 -
Evid Based Complement Alternat Med
Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification. [Abstract]2021 Nov 27:2021:7765658. PMID: 34873410 -
Evid Based Complement Alternat Med
Identifying Active Compounds and Mechanism of Camellia nitidissima Chi on Anti-Colon Cancer by Network Pharmacology and Experimental Validation. [Abstract]2021 Aug 26:2021:7169211. PMID: 34484402
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)